Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.)
Climate Impact & Sustainability Data (2017-12 to 2019-12, 2020, 2021)
Reporting Period: 2017-12 to 2019-12
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- Present data on pancreatic cancer and DIPG trials.
- Commercialization of successful drug candidates.
Medium-term Goals:
- Present data on Phase 2 OT-101 trial in treatment of COVID-19.
- Mass market EdgePoint to U.S. drug manufacturers.
Short-term Goals:
- Solidify balance sheet through financing or partnerships.
- Begin enrolling patients in Phase 3 trial for pancreatic cancer in China.
- Begin enrolling patients in pivotal trial for DIPG in the U.S.
Environmental Challenges
- Highly dilutive capital structure with significant potential for near-term dilution from conversion of preferred shares.
- Net losses every year since inception, with substantial doubt about ability to continue as a going concern without additional funding or partnerships.
- Potential for liability claims related to clinical trials.
- Competition from other biotechnology companies with greater resources.
- Uncertainty regarding market acceptance and reimbursement for drug candidates.
Mitigation Strategies
- Seeking to recapitalize and convert all preferred shares to common stock.
- Securing debt financing and non-dilutive funding for COVID-19 trial.
- Obtaining liability coverage.
- Partnering with IBM for sales and distribution of EdgePoint technology.
- Focusing on rare pediatric disease designations to reduce clinical development costs and accelerate approval.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2020
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- OT-101: Initiation of Phase 2/3 Trial in Pancreatic Cancer
- CA4P: Initiation of Phase 2 Trial in Pediatric Melanoma
- OXi4503: Initiation of Phase 2 Trial in Pediatric AML
Short-term Goals:
- Initiation of ARTI-19 in India, Africa, and Latin America; Top line data expected end of 4Q20; Application for global approval if outcome is positive.
- Initiation of C001/C002 for OT-101 against COVID-19 in Latin America; Top line data expected end of 1Q21; Application for global EUA if outcome is positive.
- Global launch of ArtiShield
Environmental Challenges
- Clinical risks associated with OT-101 and ArtiShield development for COVID-19, uncertainty of past anti-cancer trial success translating to future studies.
- Development risks due to high competition in COVID-19 therapies, success in the clinic not guaranteeing commercial success.
- Stock risk due to a large number of outstanding convertible preferred shares, significantly increasing the share count.
- Financing risk due to low cash reserves, requiring additional funding that could lead to shareholder dilution or program cuts.